GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.
- Oxbryta™ (voxelotor) Tablets Fact Sheet (pdf)
- Sickle Cell Disease Infographic (pdf)
- High resolution corporate logo (pdf)
Steven Immergut (media)